You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 26, 2024

Litigation for Patent 7,820,799

✉ Email this page to a colleague

« Back to Dashboard

US Court Litigation for Patent: 7,820,799

+ Get email alerts for changes to this table

Subscribe to access the full database, or Sign Up
Patent	Case Name	Docket	Date Filed	Date Terminated	Cause	Court	Jury Demand	Link To Docket
7,820,799	In Re: Humira (Adalimumab) Antitrust Litigation	⤷ Sign Up	2019-03-18	2020-06-30	15:1 Antitrust Litigation	District Court, N.D. Illinois	Both	⤷ Sign Up
7,820,799	Pipe Trades Services MN Welfare Fund v. AbbVie Inc.	⤷ Sign Up	2019-03-29	2019-06-06	15:1 Antitrust Litigation	District Court, N.D. Illinois	Plaintiff	⤷ Sign Up
7,820,799	⤷ Sign Up	⤷ Sign Up	2019-03-29	2019-06-06	15:1 Antitrust Litigation	District Court, N.D. Illinois	Plaintiff	⤷ Sign Up
>Patent	>Case Name	>Docket	>Date Filed	>Date Terminated	>Cause	>Court	>Jury Demand	>Link To Docket

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.